CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-703-5069460
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/21/2019 (Estimated)
OptionableOptionable
CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) issued its earnings results on Thursday, December, 20th. The company reported ($0.70) EPS for the quarter. The business had revenue of $0.13 million for the quarter. View CEL-SCI's Earnings History.
When is CEL-SCI's next earnings date?
Has CEL-SCI been receiving favorable news coverage?
News headlines about CVM stock have been trending positive recently, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CEL-SCI earned a daily sentiment score of 2.3 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the next several days.
Are investors shorting CEL-SCI?
CEL-SCI saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,871,787 shares, an increase of 11.6% from the January 15th total of 2,573,968 shares. Based on an average daily trading volume, of 295,578 shares, the short-interest ratio is presently 9.7 days. Approximately 10.4% of the company's stock are short sold. View CEL-SCI's Current Options Chain.
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include 22nd Century Group (XXII), IMV (IMV), Enochian Biosciences (ENOB), Kodiak Sciences (KOD), Monash IVF Group (MVF), IMV (IMV), ProMetic Life Sciences (PLI), OncoCyte (OCX), Emblem (EMC), BELLUS Health (BLU), Fennec Pharmaceuticals (FRX), CorMedix (CRMD), CorMedix (CRMD), Cynata Therapeutics (CYP) and BioTime (BTX).
What other stocks do shareholders of CEL-SCI own?
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the folowing people:
- Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
- Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
- Dr. Eyal Talor, Chief Scientific Officer (Age 63)
- Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
- Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (2.17%), D.A. Davidson & CO. (1.03%), Advisor Group Inc. (0.11%), Bank of New York Mellon Corp (0.05%) and Thoroughbred Financial Services LLC (0.04%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Eyal Talor, Peter R Young and Vicente Benjamin Asuncion. View Institutional Ownership Trends for CEL-SCI.
Which institutional investors are selling CEL-SCI stock?
Which institutional investors are buying CEL-SCI stock?
CVM stock was bought by a variety of institutional investors in the last quarter, including D.A. Davidson & CO., BlackRock Inc., Bank of New York Mellon Corp and Thoroughbred Financial Services LLC. View Insider Buying and Selling for CEL-SCI.
How do I buy shares of CEL-SCI?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is CEL-SCI's stock price today?
One share of CVM stock can currently be purchased for approximately $2.84.
How big of a company is CEL-SCI?
CEL-SCI has a market capitalization of $83.97 million.
What is CEL-SCI's official website?
How can I contact CEL-SCI?
CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.
MarketBeat Community Rating for CEL-SCI (NYSEAMERICAN CVM)
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote "Outperform" if you believe CVM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CVM will underperform the S&P 500 over the long term. You may vote once every thirty days.
